Trending news
Analyze
Pricing

Therapeutics

100+ Companies
Companies

Growing

148
Funding and Acquisitions

2016 Q4

22 + 2
Curators of Therapeutics
$10,000,000 Venture capital (Series A)
GeekWire

Nativis raises $10M for device that uses electromagnetic fields to mimic the effects of cancer drugs

$3,547,395 Venture capital
biospace

Modus Raises SEK 32 Million To Support Development Of Sevuparin For Sickle Cell Disease

Grant
socaltech

Neuropore Therapies Gets Grant From Michael J. Fox Foundation

Xconomy

Seattle Genetics Puts Up $250M for Immunomedics Cancer Drug Rights

GeekWire

Inside Nohla Therapeutics’ new Seattle biotech lab as Gov. Jay Inslee geeks out on science

PE Hub

Biscayne Neurotherapeutics scores $3 mln Series B - PE Hub

$3,000,000 Venture capital (Series B)
FinSMEs

Biscayne Neurotherapeutics Raises over US$3M in Series B Funding

$2,800,000 Venture capital
FinSMEs

Fibrocor Therapeutics Raises CDN$2.8m in Funding

$1,500,000 Venture capital
site1therapeutics

SiteOne Therapeutics

$1,280,000 Venture capital
vcnewsdaily

SiteOne Therapeutics Secures Investment

$14,000,000 Venture capital (Series A)
businesswire

BlackThorn Therapeutics Secures $14 Million in Series A Extension Financing | Business Wire

GeekWire

Shares of Seattle Genetics tumble after FDA places clinical hold on leukemia drug following patient deaths

$2,200,000 Seed fund
BetaKit

Appili Therapeutics raises $2.2 million to develop superbug-fighting antibiotics

Health Funding
$4,500,000 Venture capital (Series A)
FinSMEs

Circle Pharma Raises over $4.5M in Series A Funding

$43,500,000 Venture capital (Series A)
GeekWire

Fred Hutch spinout Nohla Therapeutics raises $43.5M to develop therapy for Leukemia

Health Funding
$29,500,000 Venture capital (Series G)
ENDPOINTS NEWS

CureVac grabs a $29.5M round to fuel its mRNA development efforts

Funding
£4,000,000 Venture capital
PE Hub , businesswire

Enterprise Therapeutics reels in $5 mln

$20,000,000 Post-IPO debt
FinSMEs

Cidara Therapeutics Receives $20M Credit Facility from Square 1 Bank

$145,000,000 Post-IPO equity
businesswire

Aimmune Therapeutics Announces $145 Million Equity Investment by Nestlé Health Science, Demonstrating Shared Commitment to Advancing Food Allergy Therapeutics | Business Wire

$30,895,100 Venture capital (Series B)
Techvibes , Geektime.com

Biotech Firm Raises $41 Million to Advance Cancer-Fighting Technologies